2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data provided.

**1) Return Rate Comparison with S&P 500 (VOO)**

*   **Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) solutions for end-stage organ failure patients.
*   **TMDX Cumulative Return:** 200.07%
*   **VOO (S&P 500) Cumulative Return:** 77.45%
*   **Divergence:**
    *   Current: 127.2
    *   Relative Divergence: 62.7
    *   Max: 247.2, Min: -74.5

**Analysis:** TMDX has significantly outperformed the S&P 500 over the period examined, with a cumulative return nearly 2.6 times that of the index. The current divergence is positive, indicating that TMDX is performing well relative to the S&P 500. The relative divergence of 62.7 suggests that, while the stock has performed very well compared to the S&P 500, there is still room for growth compared to its previous performance.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2019-2021  | -18.0% | 83.5%  | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%  | 83.5%  | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%  | 80.5%  | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0% | 85.5%  | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 121.0% | 85.5%  | 54.0%  | 0.3  | 4.2    |

**Analysis:** The table provides insights into TMDX's risk-adjusted performance over rolling three-year periods.

*   **CAGR (Compound Annual Growth Rate):** The CAGR varies significantly, from negative values to over 100%, highlighting the volatility of the stock. The recent CAGR is above 120%.
*   **MDD (Maximum Drawdown):** MDD is consistently high, indicating significant potential for losses during downturns. Be cautious with the stock as MDD can be very painful.
*   **Alpha:** Consistently positive alpha values demonstrate that TMDX has generally outperformed its expected return based on its beta.
*   **Beta:** Beta is very low and close to 0.0, suggesting low volatility.
*   **Cap(B):** Market Cap generally increases over time, suggesting the growth of the company's value.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 121.92
*   **Previous Close:** 123.17
*   **Change:** -1.01
*   **5-day SMA:** 124.874
*   **20-day SMA:** 129.286
*   **60-day SMA:** 126.0161

**Analysis:** The stock price has declined slightly in the last trading day. The 5-day SMA is below the 20-day SMA, and the 20-day SMA is above the 60-day SMA, suggesting a short-term downtrend but a longer-term uptrend.

**3) RSI, PPO, Market Risk Indicator, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 30.61 (Approaching Oversold)
*   **PPO:** -0.7351
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Divergence Change (20 days):** 1.1 (+), indicating a short-term upward trend.
*   **Expected Return (%):** 53.3% (over 2 years)

**Analysis:**

*   The high MRI suggests that the current market conditions are favorable for investment.
*   The RSI is nearing the oversold territory (below 30), potentially indicating a buying opportunity as the stock might be undervalued in the short term.
*   The negative PPO indicates that the short-term moving average is below the long-term moving average, suggesting a possible downtrend.
*   The hybrid signal is very strong, recommending a 100% purchase.
*   The recent positive divergence change aligns with the analyst sentiment and news, potentially signaling further short-term gains.
*   The high expected return of 53.3% suggests a positive outlook for long-term investment.

**4) Recent News & Significant Events**

*   Multiple articles highlighting TMDX as a "strong growth stock" (Yahoo Finance, Nasdaq).
*   An article stating TransMedics' stock rating was upgraded (MarketBeat).
*   An article projecting an upside of nearly 150% by the end of 2028 (Seeking Alpha).
*   News about stock options and units being granted to new hires (Stock Titan).
*   Mention as a "no-brainer growth stock to buy now" (The Motley Fool).

**Analysis:** Recent news is overwhelmingly positive, with multiple sources identifying TMDX as a strong growth stock with significant upside potential. The upgrade in stock rating and optimistic long-term projections further reinforce this positive sentiment.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean:** 1.67 (~Buy)
*   **Opinions:** 11
*   **Target Price (avg/high/low):** 144.73 / 170.00 / 114.00

**Analysis:** Analyst consensus is strongly bullish on TMDX, with a "Buy" rating and a mean score indicating a strong buy recommendation. The average target price of $144.73 suggests a significant potential upside from the current price of $121.92.

**5) Comprehensive Analysis**

TMDX presents a compelling case for investment based on the available data. Hereâ€™s a summary:

*   **Strong Outperformance:** TMDX has significantly outperformed the S&P 500, demonstrating its growth potential.
*   **Positive Analyst Sentiment:** The stock has a consensus "Buy" rating with a significant potential upside.
*   **Bullish News:** Recent news articles consistently highlight TMDX as a strong growth stock with promising future prospects.
*   **Favorable Market Conditions:** The high MRI suggests favorable investment conditions.
*   **Technical Indicators:** The RSI suggests it may be slightly oversold providing a buy opportunity.
*   **Expected High Returns:** Positive expected return based on analysis.
*   **Risks:** Despite very low Beta, MDD is constantly high, suggesting significant potential for losses during downturns. Be cautious with the stock as MDD can be very painful.

**Overall Recommendation:**

Considering the strong growth, positive analyst ratings, bullish news, and technical indicators, a **buy** recommendation seems justified for TMDX. However, investors should be aware of the potential volatility of the stock and the high MDD. Conducting further due diligence and carefully considering individual risk tolerance is recommended before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.